Trial Profile
8 Continuous vs 8 Intermittent Cycles in First and Second Line Treatment of Patients With HER2/Neu Negative, Incurable, Metastatic or Unresectable Locally Advanced Breast Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Doxorubicin liposomal (Primary) ; Paclitaxel (Primary)
- Indications Advanced breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms Stop and Go
- 23 Jul 2019 Status changed from active, no longer recruiting to completed.
- 12 Sep 2017 Safety results will be presented at the meeting as per results presented at the 42nd European Society for Medical Oncology Congress
- 12 Sep 2017 Primary endpoint has not been met. (Progression free survival) as per results presented at the 42nd European Society for Medical Oncology Congress